These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15868961)

  • 1. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer.
    Krasznai ZT; Friedländer E; Nagy A; Szabó G; Vereb G; Goda K; Hernádi Z
    Anticancer Res; 2005; 25(2A):1187-92. PubMed ID: 15868961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
    Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
    Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
    Bodey B; Taylor CR; Siegel SE; Kaiser HE
    Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay.
    Park SW; Lomri N; Simeoni LA; Fruehauf JP; Mechetner E
    Cytometry A; 2003 Jun; 53(2):67-78. PubMed ID: 12766968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
    Beck WT; Grogan TM; Willman CL; Cordon-Cardo C; Parham DM; Kuttesch JF; Andreeff M; Bates SE; Berard CW; Boyett JM; Brophy NA; Broxterman HJ; Chan HS; Dalton WS; Dietel M; Fojo AT; Gascoyne RD; Head D; Houghton PJ; Srivastava DK; Lehnert M; Leith CP; Paietta E; Pavelic ZP; Weinstein R
    Cancer Res; 1996 Jul; 56(13):3010-20. PubMed ID: 8674056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
    Shen X; Chen G; Zhu G; Fong WF
    Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
    Ho EA; Soo PL; Allen C; Piquette-Miller M
    J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of mdr1 antisense oligodeoxynucleotides on reversal of multidrug resistance in ovarian carcinoma cell line SKOV3].
    Tong Y; Pan L; Zhou S
    Zhonghua Fu Chan Ke Za Zhi; 2000 Nov; 35(11):677-9. PubMed ID: 11218898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
    Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
    Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
    Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of the MDR1 P-glycoprotein expression and function.
    Mechetner E
    Methods Mol Biol; 2007; 378():175-93. PubMed ID: 18605086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
    Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
    Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of the MDR1 gene and HSP27 in human ovarian cancer.
    Schneider J; Jimenez E; Marenbach K; Marx D; Meden H
    Anticancer Res; 1998; 18(4C):2967-71. PubMed ID: 9713493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of MDR 1 expression and CA 125 in ovarian cancer.
    Galani E; Skarlos D; Sgouros J; Litos M; Gonos E; Dionyssiou-Asteriou A
    In Vivo; 2005; 19(4):797-800. PubMed ID: 15999552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
    Li L; Jiang AC; Dong P; Wang H; Xu W; Xu C
    Ann Surg Oncol; 2009 May; 16(5):1421-8. PubMed ID: 19247716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.